Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis

Sepsis is characterized by a life-threatening organ dysfunction caused by an unbalanced host response to microbe infection that can lead to death. Besides being currently the leading cause of death in intensive care units worldwide, sepsis can also induce long-term consequences among survivors, such...

Full description

Saved in:
Bibliographic Details
Main Authors: Flora Magno de Jesus Oliveira, Cassiano Felippe Gonçalves-de-Albuquerque, Isabel Matos Medeiros de Moraes, Patrícia Alves Reis, Vinicius Novaes Rocha, Patrícia Torres Bozza, Adriana Ribeiro Silva, Hugo Caire de Castro Faria Neto
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2020/1839762
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554587333066752
author Flora Magno de Jesus Oliveira
Cassiano Felippe Gonçalves-de-Albuquerque
Isabel Matos Medeiros de Moraes
Patrícia Alves Reis
Vinicius Novaes Rocha
Patrícia Torres Bozza
Adriana Ribeiro Silva
Hugo Caire de Castro Faria Neto
author_facet Flora Magno de Jesus Oliveira
Cassiano Felippe Gonçalves-de-Albuquerque
Isabel Matos Medeiros de Moraes
Patrícia Alves Reis
Vinicius Novaes Rocha
Patrícia Torres Bozza
Adriana Ribeiro Silva
Hugo Caire de Castro Faria Neto
author_sort Flora Magno de Jesus Oliveira
collection DOAJ
description Sepsis is characterized by a life-threatening organ dysfunction caused by an unbalanced host response to microbe infection that can lead to death. Besides being currently the leading cause of death in intensive care units worldwide, sepsis can also induce long-term consequences among survivors, such as cognitive impairment. Statins (lipid-lowering drugs widely used to treat dyslipidemia) have been shown to possess pleiotropic anti-inflammatory and antimicrobial effects. These drugs act inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, the limiting step in cholesterol biosynthesis. In this work, we evaluated the therapeutic effects of simvastatin in an animal model of sepsis. In previous study from our group, statin pretreatment avoided cognitive damage and neuroinflammation in sepsis survivors. Herein, we focused on acute inflammation where sepsis was induced by cecal ligation and puncture (CLP), and the animals were treated with simvastatin (2 mg/kg) 6 h after surgery. We measured plasma biochemical markers of organ dysfunction, cell migration, cell activation, bacterial elimination, production of nitric oxide 24 h after CLP, survival rate for 7 days, and cognitive impairment 15 days after CLP. One single administration of simvastatin 6 h after CLP was able to prevent both liver and kidney dysfunction. In addition, this drug decreased cell accumulation in the peritoneum as well as the levels of TNF-α, MIF, IL-6, and IL-1β. Simvastatin diminished the number of bacterial colony forming units (CFU) and increased the production of nitric oxide production in the peritoneum. Simvastatin treatment increased survival for the first 24 h, but it did not alter survival rate at the end of 7 days. Our results showed that posttreatment with simvastatin hampered organ dysfunction, increased local production of nitric oxide, improved bacterial clearance, and modulated inflammation in a relevant model of sepsis.
format Article
id doaj-art-aba8feb8690845d283afaa5e2e8d2793
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-aba8feb8690845d283afaa5e2e8d27932025-02-03T05:51:13ZengWileyMediators of Inflammation0962-93511466-18612020-01-01202010.1155/2020/18397621839762Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental SepsisFlora Magno de Jesus Oliveira0Cassiano Felippe Gonçalves-de-Albuquerque1Isabel Matos Medeiros de Moraes2Patrícia Alves Reis3Vinicius Novaes Rocha4Patrícia Torres Bozza5Adriana Ribeiro Silva6Hugo Caire de Castro Faria Neto7Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, BrazilLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, BrazilLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, BrazilLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, BrazilLaboratório de Patologia e Histologia Veterinária, Departamento de Medicina Veterinária, Universidade Federal de Juiz de Fora, BrazilLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, BrazilLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, BrazilLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, BrazilSepsis is characterized by a life-threatening organ dysfunction caused by an unbalanced host response to microbe infection that can lead to death. Besides being currently the leading cause of death in intensive care units worldwide, sepsis can also induce long-term consequences among survivors, such as cognitive impairment. Statins (lipid-lowering drugs widely used to treat dyslipidemia) have been shown to possess pleiotropic anti-inflammatory and antimicrobial effects. These drugs act inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, the limiting step in cholesterol biosynthesis. In this work, we evaluated the therapeutic effects of simvastatin in an animal model of sepsis. In previous study from our group, statin pretreatment avoided cognitive damage and neuroinflammation in sepsis survivors. Herein, we focused on acute inflammation where sepsis was induced by cecal ligation and puncture (CLP), and the animals were treated with simvastatin (2 mg/kg) 6 h after surgery. We measured plasma biochemical markers of organ dysfunction, cell migration, cell activation, bacterial elimination, production of nitric oxide 24 h after CLP, survival rate for 7 days, and cognitive impairment 15 days after CLP. One single administration of simvastatin 6 h after CLP was able to prevent both liver and kidney dysfunction. In addition, this drug decreased cell accumulation in the peritoneum as well as the levels of TNF-α, MIF, IL-6, and IL-1β. Simvastatin diminished the number of bacterial colony forming units (CFU) and increased the production of nitric oxide production in the peritoneum. Simvastatin treatment increased survival for the first 24 h, but it did not alter survival rate at the end of 7 days. Our results showed that posttreatment with simvastatin hampered organ dysfunction, increased local production of nitric oxide, improved bacterial clearance, and modulated inflammation in a relevant model of sepsis.http://dx.doi.org/10.1155/2020/1839762
spellingShingle Flora Magno de Jesus Oliveira
Cassiano Felippe Gonçalves-de-Albuquerque
Isabel Matos Medeiros de Moraes
Patrícia Alves Reis
Vinicius Novaes Rocha
Patrícia Torres Bozza
Adriana Ribeiro Silva
Hugo Caire de Castro Faria Neto
Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis
Mediators of Inflammation
title Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis
title_full Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis
title_fullStr Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis
title_full_unstemmed Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis
title_short Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis
title_sort simvastatin posttreatment controls inflammation and improves bacterial clearance in experimental sepsis
url http://dx.doi.org/10.1155/2020/1839762
work_keys_str_mv AT floramagnodejesusoliveira simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis
AT cassianofelippegoncalvesdealbuquerque simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis
AT isabelmatosmedeirosdemoraes simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis
AT patriciaalvesreis simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis
AT viniciusnovaesrocha simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis
AT patriciatorresbozza simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis
AT adrianaribeirosilva simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis
AT hugocairedecastrofarianeto simvastatinposttreatmentcontrolsinflammationandimprovesbacterialclearanceinexperimentalsepsis